

Determination of Phenolic Contents by HPLC, and Antioxidant, Antimicrobial, Antityrosinase, and Anticholinesterase Activities of *Psephellus huber-morathii*

Running Title: Biological Activity of *Psephellus huber-morathii*

ABSTRACT

The goal of our study was to examine of antioxidant, antimicrobial, anticholinesterase activities, and phenolic composition of *Psephellus huber-morathii*. The antioxidant activities of extracts have been assessed by Ferric reducing antioxidant power (FRAP), cupric reducing antioxidant capacity (CUPRAC), and 2,2-diphenylpicrylhydrazyl (DPPH) radical scavenging. Phenolic constituents were measured using reverse phase-high performance liquid chromatography (RP-HPLC), and antimicrobial activity was investigated using the agar well diffusion method. Total phenolic content, FRAP, and CUPRAC results of aqueous extract have been better than methanolic extract, except for DPPH activity. Benzoic acid, and *p*-coumaric acid as major phenolic compounds were specified. Methanolic extract was especially effective against all microorganisms tested except for *Yersinia pseudotuberculosis*. The methanolic extract have been displayed inhibitory effect on tyrosinase. All extracts have been exhibited lower acetylcholinesterase, and butyrylcholinesterase inhibitory activities than galantamine. *P. huber-morathii* can be considered in the food, and drug industries due to antioxidant capacity and antimicrobial activities of the species. It can be potential source as anti-browning agents because of its average tyrosinase inhibitory activity.

Keywords: Antioxidant, Antimicrobial, anticholinesterase, *Psephellus huber-morathii*

42 1. INTRODUCTION

43 Free radicals, particularly oxygen free radicals (OFRs) or reactive oxygen species (ROS) (such as
44 superoxide, hydroxyl and hydrogen peroxide), are active oxygen compounds produced by the
45 oxidation reactions of external factors [1]. These reactive species are liable for oxidizing proteins, lipids
46 and DNA, and of triggering various degenerative and chronic disorders [2-5]. Antioxidants can
47 suppress or delay oxidation when present at lower levels than oxidizable substrates [6]. They are
48 prominent to preserve human health and averting free radical-induced disease. The health benefits of
49 antioxidants are so great that foodstuffs and pharmaceutical products are routinely reinforced with
50 synthetic antioxidant supplements, including BHA, BHT and PG. However, synthetic antioxidants
51 may have carcinogenic and other toxic side-effects [7]. Natural antioxidants are for that reason
52 currently preferred to synthetic equivalents, and limitations on the use of the latter have been
53 recommended.

54 Alzheimer's disease (AD) known by memory disturbance is a widespread neurodegenerative
55 disease. The most prominent biochemical change in the disease is a decrease in cerebral
56 acetylcholine levels [8]. Raising acetylcholine levels, by means of suppression of the two principal form
57 of cholinesterase, acetylcholinesterase (AChE) and butyrylcholinesterase, can therefore be adopted as
58 a therapeutic approach in AD (BChE) [9]. Agents used to inhibit cholinesterase in the treatment of AD
59 include tacrine, rivastigmine and galantamine. However, side-effects have also been observed with
60 these compounds, particularly hepatotoxicity and gastrointestinal disturbances [10,11]. There has
61 therefore been growing focus on safe and effective AChE inhibitors obtained from natural products.

62 *Psephellus huber-morathii* (Wagenitz) Wagenitz, otherwise known as *Centaurea huber-morathii*
63 Wagenitz, is a member of the Asteraceae family. The genus *Centaurea* (Asteraceae) consists of some
64 500 species distributed in the Old World [12]. On the Anatolian peninsula, the genus is represented by
65 approximately 190 species, more than 100 of which are endemic [13]. Some *Centaurea* species are
66 employed as herbal therapies for fever, diabetes, hemorrhoid, and peptic ulcer in traditional Anatolian
67 folk medicine [14,15]. Pharmacological and phytochemical studies of various different *Centaurea*
68 species have identified antioxidant, antimicrobial and antipyretic properties [16-19].

69 The aims of this work were firstly, the gain of more information about total phenolic quantity, the study
70 of the potential natural antioxidant, antimicrobial, antityrosinase, antiacetylcholinesterase,
71 antibutyrylcholinesterase effect of extracts of *P. huber-morathii*, secondly to carry on the relationships
72 between total phenolic content and studied activities.

73 **2. MATERIAL AND METHODS**

74 **2.1. Chemicals and Instrumentation**

75 The following chemicals and reagents were used: 2,2-Diphenyl-1-picrylhydrazyl (DPPH), and 3-(4,5-
76 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich); butylated hydroxytoluene
77 (BHT) (Supelco); galanthamine (Sigma); methanol, ethanol, acetic acid, dimethyl sulfoxide, and
78 acetonitrile (Merck); 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), 2,4,6-tripyridyl-
79 s-triazine (TPTZ), and Folin–Ciocalteu reagent (Fluka); polytetrafluoroethylene membranes
80 (Sartorius).

81 Absorbance was calculated using a Spectro UV-Vis Double PC-8 auto cell spectrophotometer
82 (Labomed Inc.). All solutions were prepared with deionized water purified in an Elgacan® C114 Ultra
83 Pure Water System Deioniser (The Elga Group, Buckinghamshire, England).

84 Evaporation procedures were conducted using the IKA® RV 05 Basic (IKA®, Werke, USA) rotary
85 evaporator system, while extraction was carried out with a Heidolph promax 2020 shaker. All dissolution
86 procedures involved the use of a Heidolph Reax top vortex and Elma® Transsonic Digital ultrasonic
87 water bath (Germany). A Hanna Instruments microprocessor pH meter was employed where
88 appropriate.

89 **2.2. Plant Material and Preparation of Samples**

90 *P. huber-morathii* were collected in 2016 from the Erzincan (Turkey), and identified by one of the
91 authors (Ali Kandemir). The voucher specimens were kept in the herbarium of Erzincan University,
92 Faculty of Science (herbarium number: 10862). Dried and powdered plant was extracted in methanol
93 during a day. The extract was evaporated with a rotary evaporator (IKA-Werke RV05 Basic, Staufen,
94 Germany). The obtained extract was used for antioxidant, antimicrobial, cytotoxicity,

95 anticholinesterase, and antityrosinase activity studies. The extract for use in HPLC analysis was
96 further dissolved in HPLC grade methanol (10 mg/mL) and filtered through 0.45- μ m membranes filter.

97 2.3. HPLC Conditions

98 The standards including vanillic acid, *p*-hydroxybenzoic acid, syringaldehyde, *p*-coumaric acid, sinapic
99 acid, benzoic acid and quercetin were used for HPLC analysis. HPLC analysis of phenolic compounds
100 was conducted on a reverse phase column (150 \times 4.6 mm i.d, 5 μ m) (Waters Spherisorb, Milfort, MA,
101 USA), on a gradient program with the assistance of a two-solvents system [A: 100% methanol; B: 2%
102 acetic acid in water (pH 2.8)], and a constant solvent flow rate set to 1.5 mL min⁻¹ on a HPLC system
103 (Shimadzu Corporation, LC 20 AT, Kyoto, Japan) (Table 1). The injection volume was adjusted to 20
104 μ L. Signals were identified at 232, 246, 260, 270, 280, 290, 308, and 328 using DAD detection at a
105 column temperature of 25°C. HPLC analyses were carried out using validated and modified methods
106 in our previous study [20,21].

107 2.4. Detection of Antioxidant Capacity

108 The Folin-Ciocalteu procedure was performed in order to calculate total phenolic quantities in the
109 extract [22]. Gallic acid was used as a positive standard, with the total phenolic content being
110 expressed as mg of gallic acid equivalents per gram of 100 g sample. Briefly, 0.01, 0.02, 0.03, 0.04
111 and 0.05 mg/mL concentrations of gallic acid were dissolved in methanol. 0.5 mL of each sample was
112 placed into test tubes, and then added 0.5 mL of 0.2 N Folin-Ciocalteu reagent and 1.5 mL of 2%
113 sodium carbonate. The test tubes were incubated for 2 h at 20 °C, after which the absorbance was
114 evaluated spectrophotometrically at 760 nm. All measurements were conducted in triplicate.

115 The ferric reducing antioxidant power (FRAP) assay depends on calculating the iron reducing
116 capacities of a given extract [23]. When exposed to 2,4,6-tripyridyl-S-triazine (TPTZ), the Fe²⁺-TPTZ
117 complex exhibits a blue color which is read at 593 nm. Briefly, 3.0 mL of fresh FRAP reagent was
118 added to an appropriate volume/concentration of extract. The samples was incubated for 4 min at 37
119 °C, after which the absorbance was measured at 593 nm. Trolox was also measured under identical
120 conditions as a standard antioxidant compound for purposes of comparison. The results were stated
121 as μ M Trolox equivalent of g sample.

122 DPPH radical-scavenging activity is **connected** to the antioxidant's DPPH radical scavenging capacity
123 [24]. In brief, we added 0.75 mL of DPPH reagent (0.1 mM in methanol) to 0.75 mL of extract or
124 standard, and mixed. The samples were incubated in the dark for 30 mins at room temperature.
125 **Observed discoloration** was measured spectrophotometrically at 517 nm. The percentage inhibitions of
126 the discoloration of the extracts were compared with BHT (Butyllated hydroxytoluene) used as
127 standard. **The results were expressed as SC₅₀** (mg sample per mL).

128 The CUPRAC levels of extracts were studied spectrophotometrically [25]. Briefly, 1 mL of CuCl₂
129 solution (1.0x10⁻² M), 1 mL of neocuproine solution (7.5x10⁻³ M) and 1 mL NH₄Ac buffer solution were
130 mixed in a test tube. A range of different extract concentrations were added. The test tubes were then
131 incubated for 30 mins. Absorbance was measured at 450 nm against a reagent blank. CUPRAC
132 values were expressed as µM Trolox equivalent per gram of sample.

133 **2.5. Antimicrobial Activity Assessment**

134 *Escherichia coli* ATCC 25922, *Yersinia pseudotuberculosis* ATCC 911, *Pseudomonas auroginosa*
135 ATCC 43288, *Staphylococcus aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212, *Listeria*
136 *monocytogenes* ATCC 43251, *Bacillus cereus* 709 ROMA, *Mycobacterium smegmatis* ATCC607,
137 *Candida albicans* ATCC 60193, and *Saccharomyces cerevisiae* RSKK 251 were supplied by the
138 Hizissihha Institute of Refik Saydam (Ankara, Turkey). We dissolved the extract in dimethyl sulfoxide
139 (DMSO) for material preparation in a stock solution of 178–256 mg/mL.

140 The agar-well diffusion method [26], with various modifications previously described elsewhere [27],
141 was used for susceptibility screening. Each bacterium was suspended in Mueller Hinton (MH) (Difco,
142 Detroit, MI) broth, while yeast-like fungi were suspended in yeast extracts broth. The micro-organisms
143 were subsequently diluted to a level of approximately 10⁶ colony-forming units (cfu) per mL.
144 Sabouraud Dextrose Agar (SDA) (Difco, Detroit, MI) was used for yeast-like fungi, and brain heart
145 infusion agar (BHA) was employed for *M. smegmatis* [28]. These were "flood-inoculated" onto the
146 surface of MH and SD agars and then dried. In the following stage, 5-mm diameter wells were
147 produced from the agar with the help of a sterile cork-borer, after 8900- 12800 µg/50 µL of the extract
148 substances was placed into the wells. The plates were incubated for 18 h at 35 °C. *M. smegmatis* was
149 cultured for 3-5 days on BHA plates at 35 °C. The zone of inhibition was measured against the test

150 organism to determine antimicrobial activity. Ampicillin (10 µg), streptomycin (10 µg), and fluconazole
151 (5 µg) were employed as standard drugs, while dimethylsulfoxide served as the control. Finally,
152 minimal inhibition concentration (µg mL⁻¹) of *P. huber-morathii* were calculated.

153 **2.6. Antityrosinase Activity**

154 Tyrosinase inhibitory activity (TIA) (EC 1.14.1.8.1, 30 U, mushroom tyrosinase, Sigma) was measured
155 using different concentrations of kojic acid solutions as standard [29]. Reaction mixture absorbance
156 was read at 490 nm using the spectrophotometric method via a microplate reader (VersaMax
157 Molecular Devices, USA). The percentage of TIA was calculated using the formula % inhibition = $[(A-$
158 $B)-(C-D)] / (A-B) \times 100$

159 **2.7. Acetylcholinesterase (AChE)/Butyrylcholinesterase (BChE) Inhibitory Activity**

160 The modified colorimetric Ellman method was used to investigate acetylcholine esterase inhibitory
161 (AChEI) and butyrylcholin esterase inhibitory (BChE) activities [30]. AChE and BChE were employed
162 as enzymes. Acetylthiocholine iodide and butyrylthiocholine iodide as substrates were used. Also, 5,5'-
163 dithio-bis 2-nitrobenzoic acid (DTNB) was used as the coloring agent. The control and test compounds
164 were dissolved in sodium phosphate buffer (pH 8) range of concentration of 25-200 µg/mL. Next, 130
165 µL of sodium phosphate buffer, 10 µL of the tested compound and 20 µL of the enzyme were mixed in
166 a 96-well plate and incubated for 15 min at 25 °C. In the following procedure, 20 µL of DTNB and 20
167 µL of substrats were added to all wells. Absorbance was measured spectrophotometrically at 412 nm.
168 AChE and BChE inhibition values were calculated using the formula shown below and compared
169 against galantamine used as standard.

$$170 \quad \% \text{ Inhibition} = 100 - [(A1 / A2) \times 100]$$

171 A1 = Absorbance of the sample solutions at 412 nm

172 A2 = Average absorbance of the control solutions at 412 nm.

173 **3. RESULTS**


174 **3.1. HPLC Chromatograms**

175 Chromatograms of the phenolic standards and methanolic extract have been presented in Figures 1-2.
176 The quantities of phenolic compounds measured in the samples have been shown in Table 1. As
177 shown in the table, *p*-coumaric acid and benzoic acid have been detected in the methanolic extract of
178 the plant.

179 **Table 1. Phenolic composition of the methanolic extract of *P. huber-morathii***

Phenolic compounds	Retention time (min)	Amount (mg/g)
<i>p</i> -hydroxy benzoic acid	4.411	-
Vanillic acid	5.102	-
Syringaldehyde	6.383	-
<i>p</i> -coumaric acid	7.437	2.21
Sinapic acid	7.947	-
Benzoic acid	9.588	11.55
Quercetin	14.720	-


180
181
182



183
184
185
186
187
188

Fig. 1. HPLC chromatogram of phenolic standards

Peak identification: (1) *p*-hydroxy benzoic acid, (2) vanillic acid, (3) syring aldehyde, (4) *p*-coumaric acid, (5) sinapic acid, (6) benzoic acid, (7) quercetin.



189
190
191 **Fig. 2. HPLC chromatogram of *P. huber-morathii* methanol extract**

Peak identification: (4) *p*-coumaric acid, (6) benzoic acid.

192
193
194
195 **3.2. Antioxidant Activities of *P. huber-morathii* Extracts**

196 **The results of TPC, FRAP, CUPRAC and DPPH scavenging activity studies of the aqueous and**
197 **methanolic extracts have been defined in Table 2.**

198 **Table 2. The antioxidant activities of *P. huber-morathii* extracts**

Test Compounds	TPC [†]	FRAP [‡]	CUPRAC [§]	DPPH ²
Aqueous extract	13.9 ± 0.460	841 ± 4.699	1322 ± 8.940	0.3379 ± 0.0049
Methanolic extract	10 ± 0.268	666 ± 3.210	1230 ± 7.915	0.2073 ± 0.0036
BHT				0.0031 ± 0.0002

199 [†]Total phenolic content expressed in mg of gallic acid equivalent (GAE) per gram of dry plant weight.

200 [‡] FRAP value expressed as μM trolox equivalents (TE) per gram of dry plant weight.

201 [§] Trolox equivalent antioxidant capacity (TEAC) value expressed in μM trolox equivalents (TE) per
202 gram of dry plant weight.

203 ^{||2} Concentration of test sample (mg/mL) required to produce 50% inhibition of the DPPH radical.

204 **3.3. Antimicrobial Activities of *P. huber-morathii* Extracts**

205 The antimicrobial activities of *P. huber-morathii* extracts against the bacteria and fungus tested was
 206 assessed in terms of the presence of minimal inhibition concentrations (Table 3). The methanolic
 207 extract exhibited antimicrobial effect against *E. coli*, *P. aeruginosa*, *S. aureus*, *E. faecalis* and *M.*
 208 *smegmatis*, but not *Y. pseudotuberculosis*.

209 **Table 3. Antimicrobial activities of *P. huber-morathii* extracts**

Tested Compounds	Microorganisms and Minimal Inhibition Concentration (µg/mL)										
	Quantity (µg/mL)	Gram negative			Gram positive				No gram	Yeast Like Fungi	
		Ec	Yp	Pa	Sa	Ef	Lm	Bc	Ms	Ca	Sc
Methanolic Extract	10000	125	-	250	250	350	700	350	62.25	350	350
Aqueous Extract	10000	-	-	-	-	-	-	-	-	-	-
Ampicillin	10	10	18	>128	35	10	10	15	-	-	-
Streptomycin	10								4		
Fluconazole	5									>8	>8

210 Ec: *Escherichia coli* ATCC 25922, Yp: *Yersinia pseudotuberculosis* ATCC 911, Pa: *Pseudomonas*
 211 *aeruginosa* ATCC 27853, Sa: *Staphylococcus aureus* ATCC 25923, Ef: *Enterococcus faecalis* ATCC
 212 29212, Lm: *Listeria monocytogenes* ATCC 43251, Bc: *Bacillus cereus* 702 Roma, Ms: *Mycobacterium*
 213 *smegmatis* ATCC607, Ca: *Candida albicans* ATCC 60193, Sc: *Saccharomyces cerevisiae* RSKK 251, (-):
 214 no activity of test concentrations (10 000 µg/mL).

215 3.3. Antityrosinase Activity of *P. huber-morathii* Extract

216 We investigated the antityrosinase activity of *P. huber-morathii* extract. The IC₅₀ value of the
 217 methanolic extract were found as 575.44 µg/mL, while IC₅₀ value of kojic acid as positive standart,
 218 were 3.0957 µg/mL.

219 3.4. Anticholinesterase Activities of *P. huber-morathii* Extracts

220 We also investigated the AChE, and BChE inhibitory activities of *P. huber-morathii* extracts. AChE and
 221 BChE inhibitory activity of the extracts and positive standard galantamine were specified in Table 4.

222 **Table 4. Acetylcholinesterase (AChE), and butyrylcholinesterase (BChE) inhibitor activities (%**
 223 **inhibition)**

	Samples	25 µg/mL	50 µg/mL	100 µg/mL	200 µg/mL
AChE Inhibitory Activity	AE	9.2 ± 0.5	15.5 ± 0.4	24.9 ± 0.2	30.4 ± 0.8
	ME	3.4 ± 0.7	8.3 ± 0.3	27.8 ± 0.5	38.8 ± 0.7
	Galantamine	64.5±1.2	72.2±0.9	78.6±0.8	84.2 ± 0.3

	AE	21.0 ± 0.2	46.8 ± 0.4	55.3 ± 0.8	68.3 ± 1.3
BChE Inhibitory Activity	ME	10.5 ± 0.4	32.1 ± 0.6	54.9 ± 0.9	72.6 ± 1.5
	Galantamine	41.3±0.7	56.6±0.8	68.7±1.2	80.1 ± 0.4

224 **AE:** Aqueous extract; **ME:** Methanolic extract

225 4. DISCUSSION

226 Phenolic compounds have been increased popularity for health-promoting effects due to their
 227 antioxidant properties. The most widespread types of phenolic compounds in natural sources have
 228 been known as phenolic acids and flavonoids [31].

229 According to HPLC analyses, among the phenolic acids, benzoic acid, and *p*-coumaric acid have been
 230 detected. *p*-Coumaric acid is a phenolic acid belongs to hydroxycinnamic acid family and important for
 231 health care because of antioxidant, anti-inflammatory, antimutagenic, antiulcer, antiplatelet,
 232 antidiabetic and anticancer activities. Also it has been reported to reduce oxidative cardiac damage
 233 and atherosclerosis [32]. Benzoic acid and derivatizations have been reported to show antibacterial
 234 and antifungal activity and significant antioxidant capacity. Benzoic acid have been used as food
 235 preservation because of these properties [33,34].

236 *P. huber-morathii* have been also known as *Centaurea huber-morathii*. It has been reported that the
 237 determination of total phenolic contents, free radical scavenging activity, cupric ion reducing power
 238 and ferric reducing antioxidant power was carried on some different *Centaurea* species [17,18, 35-39].
 239 Besides, there have been noticeable research into the antimicrobial activities of different *Psephellus*
 240 species. In previously studies, *Centaurea* species have been reported significant antibacterial and
 241 antifungal activities [40-43].

242 As shown the results of antioxidant capacity studies of the aqueous and methanolic extract of the
 243 species, the total phenolic contents have been possessed of considerable values. Furthermore, FRAP,
 244 CUPRAC and DPPH scavenging activity belong to the species have been observed to be important.
 245 The results from HPLC and antioxidant activity studies have been compatible. Antioxidant capacity of
 246 *P. huber-morathii* may be based on its phenolic compounds.

247 The methanolic extract of the species has showed high antimicrobial activity on *E. coli*, *P. aeruginosa*,
248 *S. aureus*, *E. faecalis* and *M. smegmatis* microorganisms caused a wide range of diseases. As
249 mentioned above, the high antimicrobial activity of the plant can be related with benzoic acid.

250 Tyrosinase is a substantial enzyme in the production of melanin. Melanin protects cutaneous tissues
251 against ultraviolet (UV) damage by reducing reactive oxygen species. Overproduction or abnormal
252 melanin pigmentation have given rise to cosmetic concerns in humans. So, potent tyrosinase inhibitors
253 have need to be developed [44]. The IC₅₀ value of the methanolic extract on tyrosinase was calculated
254 at 575.44 µg/mL. These findings have indicated that *P. huber-morathii* extract may have been a
255 potential natural source to design and develop of novel tyrosinase inhibitors as anti-browning agents.

256 AChE and BChE inhibitory activity of some *Centaurea* species have been reported at previously
257 studies, while the ChE inhibitory activity of *P. huber-morathii* have been examined for the first time with
258 this study [45].

259 AChE inhibitors have been used for treatment of Alzheimer's disease. Recent studies have also
260 looked for novel AChE inhibitors from natural sources [46]. So, Cholinesterase inhibitory activity of the
261 species has been performed. The results have showed that the extracts have been possessed lower
262 acetylcholinesterase inhibitory and closer butyrylcholinesterase inhibitory activities, compared with
263 galantamine. So, further researches have been necessary to determine for treatment Alzheimer's
264 disease of the plant.

265 5. CONCLUSION

266 In the present study, all biological activities of *P. huber-morathii* have been examined for the first
267 time. Novel plant-derived bioactive molecules have been urgently needed, and these plant extracts
268 may represent a natural source of antioxidants and antimicrobial agents, particularly in foodstuffs and
269 medicinal products. Further studies have been needed to confirm the bioactive compounds related to
270 antioxidant, antimicrobial, and anticholinesterase activities observed in these extracts.

271

272

273 **CONFLICT OF INTEREST**

274 The authors declare that there are no conflicts of interest

275 **ACKNOWLEDGEMENTS**

276 Merve Badem, Sıla Özlem Şener and Nuriye Korkmaz would like to acknowledge the scholarship by
277 the Turkish Scientific and Technical Research Council.

278 **References**

279 1. Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. Arch Biochem
280 Biophys. 1990;280:1-8.

281 2. Lee J, Koo N, Min DB. Reactive oxygen species, aging, and antioxidative nutraceuticals.
282 Compr Rev Food Sci Food Saf. 2004;3:21-33.

283 3. Mantena RKR, Wijburg OLC, Vindurampulle C, Bennett-Wood VR, Walduck A, Drummond
284 GR, Davies JK, Robins-Browne RM, Strugnell RA. Reactive oxygen species are the major
285 antibacterials against Salmonella typhimurium purine auxotrophs in the phagosome of RAW
286 264.7 cells. Cell Microbiol. 2008;10:1058-1073.

287 4. Sevindik M, Akgul H, Pehlivan M, Selamoglu Z. Determination of therapeutic potential of
288 *Mentha longifolia* ssp. *longifolia*. Fresen Environ Bull. 2017;26:4757-4763.

289 5. Pehlivan M, Sevindik M. Antioxidant and Antimicrobial Activities of *Salvia multicaulis*.
290 TURJAF. 2018;6(5):628-631.

291 6. Sikorski ZE. Chemical and Function Properties of Food Components. CRC Press; New
292 York; 2001.

293 7. Barlow S, Schlatter J. Risk assessment of carcinogens in food. Toxicol Appl Pharmacol.
294 2010;43:180-190.

295 8. Sevindik M. Investigation of Antioxidant/Oxidant status and antimicrobial activities of
296 *Lentinus tigrinus*. Adv in Pharma Sci. 2018; <https://doi.org/10.1155/2018/1718025>.

297 9. Jaen JC, Gregor VE, Lee C, Davis R, Emmerling M. Acetylcholinesterase inhibition by
298 fused dihydroquinazoline compounds. Bioorg Med Chem Lett. 1996;6:737-742.

- 299 10. Schulz V. Ginkgo extract or cholinesterase inhibitors in patients with dementia: what
300 clinical and guidelines fail to consider. *Phytomedicine*. 2003;10:74-79.
- 301 11. Melzer D. New drug treatment for Alzheimer's diseases: lessons for healthcare policy.
302 *BMJ*. 1998;316:762-764.
- 303 12. Dittrich M. *Cinareae*-systematic review. In: Heywood VH, Harborne JB, Turner BL,
304 editors. *The biology and chemistry of the Compositae*. Academic Press: London, New York,
305 San Francisco; 1977.
- 306 13. Davis PH. *Flora of Turkey and the East Aegean Islands*, vol. 10. Edinburgh University
307 Press: Edinburgh; 1988.
- 308 14. Kargioglu M, Cenkci S, Serteser A, Evliyaoglu N, Konuk M, Kok MS, Bagcı Y. An
309 ethnobotanical survey of interior-West Anatolia, Turkey. *Hum Ecol*. 2008;36:763-777.
- 310 15. Honda G, Yesilada E, Tabata M, Sezik E, Fujita T, Takeda Y, Takaishi Y, Tanaka T.
311 Traditional medicine in Turkey VI. Folk medicine in West Anatolia: Afyon, Kutahya, Denizli,
312 Mugla, Aydin provinces. *J Ethnopharmacol*. 1996;53:75-87.
- 313 16. Tepe B, Sokmen M, Akpulat HA, Yumrutas O, Sokmen A. Screening of antioxidative
314 properties of the methanolic extracts of *Pelargonium endlicherianum* Fenzl., *Verbascum*
315 *wiedemannianum* Fisch. & Mey., *Sideritis libanotica* Labill. subsp. *linearis* (Bentham) Borm.,
316 *Centaurea mucronifera* DC. and *Hieracium cappadocicum* Freyn from Turkish Flora. *Food*
317 *Chem*. 2006;98:9-13.
- 318 17. Zengin G, Guler GO, Cakmak YS, Aktumsek A. Antioxidant capacity and fatty acid profile
319 of *Centaurea kotschyi* (Boiss. & Heldr.) Hayek var. *persica* (Boiss.) Wagenitz from Turkey.
320 *Grasas Aceites*. 2011;62:90-95.
- 321 18. Tekeli Y, Sezgin M, Aktumsek A. Antioxidant property of *Centaurea solstitialis* L. from
322 Konya, Turkey. *Asian J Chem*. 2008;20:4831-4835.
- 323 19. Koca U, Suntar IP, Keles H, Yesilada E, Akkol EK. *In vivo* antiinflammatory and wound
324 healing activities of *Centaurea iberica* Trev. ex Spreng. *J Ethnopharmacol*. 2009;126:551-
325 556.
- 326 20. Kanbolat Ş, Korkmaz N, Şener SÖ., Badem M, Ulaş Çolak N, Abudayyak M, et al.
327 Antioxidant, antimicrobial, cytotoxic, anticholinesterase, antityrosinase activities and

- 328 characterisation of volatile compounds of *Verbascum oocarpum* by SPME and GC-FID/MS.
329 Journal of Pharmaceutical Research International. 2018;24:1-12.
- 330 21. Korkmaz N., Şener SÖ., Kanbolat Ş, Badem M, Aliyazicioğlu R, Abudayyak M, et al.
331 Investigation of antioxidant, cytotoxic, tyrosinase inhibitory activities, and phenolic profiles of
332 green, white, and black teas. Turkish Journal of Biochemistry. 2019;44. In press.
- 333 22. Singleton VL, Rossi JAJr. Colorimetry of total phenolics with phosphomolybdic
334 phosphotungstic acid reagents. Am J Enol Viticult. 1965;16:144-58.
- 335 23. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of
336 "antioxidant power": the FRAP assay. Anal Biochem. 1996;239: 70-6.
- 337 24. Molyneux P. The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for
338 estimating antioxidant activity. Songklanakarin J Sci Technol. 2004;26:211-9.
- 339 25. Apak R, Guclu K, Ozyurek M, Karademir SE, Erca E. The cupric ion reducing antioxidant
340 capacity and polyphenolic content of some herbal teas. Int J Food Sci Nutr. 2006;7:292-304.
- 341 26. Perez C, Pauli M, Bazerque P. An antibiotic assay by the well agar method. Acta Biol
342 Exp. 1990;15:113-115.
- 343 27. Ahmad I, Mehmood Z, Mohammed F. Screening of some Indian medicinal plants for their
344 antimicrobial properties. J Ethnopharmacol. 1998;62:183–193.
- 345 28. Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, Pfyffer GE, Ridderhof JC,
346 Wallace RJ, Warren NC, Witebsky FG. In susceptibility testing of mycobacteria, nocardiae,
347 and other aerobic actinomycetes; approved standard, NCCLS document 2003;M24-A.
- 348 29. Masuda T, Yamashita D, Takeda Y, Yonemori S. Screening for tyrosinase inhibitors
349 among extracts of seashore plants and identification of potent inhibitors from *Garcinia*
350 *subelliptica*. Biosci Biotechnol Biochem. 2005;69:197-201.
- 351 30. Ellman GL, Courtney DK, Andres JRV, Featherstone RM. A new and rapid determination
352 of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88-95.
- 353 31. Gutiérrez-Grijalva EP, Ambriz-Pérez DL, Leyva-López N, Castillo-López RI, Heredia JB.
354 Dietary phenolic compounds, health benefits and bioaccessibility. Archivos Latinoamericanos
355 de Nutricion. 2016;66:2.

- 356 32. Pei K, Ou J, Huang J, Ou S. p-Coumaric acid and its conjugates: dietary sources,
357 pharmacokinetic properties and biological activities. *Journal of the Science of Food and*
358 *Agriculture*. 2016;96:2952-2962.
- 359 33. Mohamed SAİD, Kordali Ş, Korkmaz M. Evaluation of the effect of benzoic acid on some
360 plant pathogenic fungi. *Uluslararası Tarım ve Doğa Bilimleri Dergisi*, 1(1), 3-5.)
- 361 34. Velika B, Kron I. Antioxidant properties of benzoic acid derivatives against superoxide
362 radical. *Free Radicals and Antioxidants*. 2012;2: 62-67
- 363 35. Karamenderes C, Konyalioglu S, Khan S, Khan IA. Total phenolic contents, free radical
364 scavenging activities and inhibitory effects on the activation of NF-kappa B of eight
365 *Centaurea* L. species. *Phytother Res*, 2007;21:488-491.
- 366 36. Ugur A, Duru ME, Ceylan O, Sarac N, Varol O, Kivrak I. Chemical composition,
367 antimicrobial and antioxidant activities of *Centaurea ensiformis* Hub.-Mor (Asteraceae), a
368 species endemic to Mugla (Turkey). *Nat Prod Res*. 2009;23:149-167.
- 369 37. Borneo R, Leon AE, Aguirre A, Ribotta P, Cantero JJ. Antioxidant capacity of medicinal
370 plants from the Province of Co'rdoba (Argentina) and their in-vitro testing in a model food
371 system. *Food Chem*. 2009;112:664-670.
- 372 38. Nickavar B, Kamalinejad M, Haj-Yahya M, Shafaghi B. Comparison of the free radical
373 scavenging activity of six Iranian *Achiella* species. *Pharm Biol*. 2006;44:208-212.
- 374 39. Zengin G, Aktumsek A, Guler GO, Cakmak YS, Kan Y. Composition of essential oil and
375 antioxidant capacity of *Centaurea drabifolia* Sm. subsp. *detonsa* (Bornm.) Wagenitz,
376 endemic to Turkey. *Nat Prod Res*. 2012;26:1-10.
- 377 40. Guven K, Celik S, Uysal I. Antimicrobial Activity of *Centaurea* species. *Pharm Biol*.
378 2005;43(1):67-71,
- 379 41. Kumarasamy Y, Middleton M, Reid RG, Nahar L, Sarker SD. Biological activity of
380 serotonin conjugates from the seeds of *Centaurea nigra*. *Fitoterapia*. 2003;74:609-612.
- 381 42. Cansaran A, Dogan NM, Oztekin M, Acar G. Antimicrobial activity of various extracts of
382 *Centaurea cankiriense* A. Duran and H. Duman. *Afr J Microbiol Res*. 2010;4:608-612.

- 383 43. Sarker SD, Kumarasamy Y, Shoeb M, Celik S, Yucel E, Middleton M, Nahar L.
384 Antibacterial and antioxidant activities of three Turkish species of the genus *Centaurea*.
385 OPEM 2005;5:246-250.
- 386 44. Nguyen HX, Nguyen NT, Nguyen MHK, Le TH, Van Do NT, Hung TM, Nguyen MTT.
387 Tyrosinase inhibitory activity of flavonoids from *Artocarpus heterophyllous*. Chem Cent J.
388 2016;10:1-6.
- 389 45. Aktumsek A, Zengin G, Ozmen Guler G, Cakmak YS, Duran A. Antioxidant potentials
390 and anticholinesterase activities of methanolic and aqueous extracts of three endemic
391 *Centaurea* L. species. Food Chem Toxicol. 2013;55:290-296.
- 392 46. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol
393 Res. 2004;50:433-440.

UNDER PEER REVIEW